NEUROCRINE BIOSCIENCES INC (NBIX) — SEC Filings

Latest SEC filings for NEUROCRINE BIOSCIENCES INC (NBIX), explained in plain English.

Sentiment Overview: 3 bullish, 24 neutral

Recent Filings (27)

• 8-K Filing — 8-K · 2026-04-06T07:35:19-04:00 [neutral]
• 8-K Filing — 8-K · 2025-11-24T00:00:00.000Z [neutral]
• Neurocrine's Q3 Net Income Soars 61% on Strong Product Sales — 10-Q · 2025-10-28T00:00:00.000Z [bullish] Risk: medium
  NEUROCRINE BIOSCIENCES INC (NBIX) reported a strong financial performance for the three months ended September 30, 2025, with total revenues increasing to $794.
• Neurocrine's Q2 Sales Surge, Collaboration Revenue Doubles — 10-Q · 2025-07-30T00:00:00.000Z [bullish] Risk: medium
  NEUROCRINE BIOSCIENCES INC reported a significant increase in product sales for the three months ended June 30, 2025, reaching $510.0 million, up from $430.0 mi
• Neurocrine Biosciences Files 8-K on Officer/Director Changes — 8-K · 2025-05-30T00:00:00.000Z [neutral] Risk: low
  Neurocrine Biosciences, Inc. filed an 8-K on May 30, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of ce
• Neurocrine Biosciences Announces Executive and Board Changes — 8-K · 2025-05-22T00:00:00.000Z [neutral] Risk: medium
  Neurocrine Biosciences, Inc. announced on May 21, 2025, several key executive and board changes. These include the departure of Director Dr. Richard H. Scheller
• Neurocrine Biosciences Q1 2025 Update — 10-Q · 2025-05-05T00:00:00.000Z [neutral] Risk: low
  Neurocrine Biosciences Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's financial filings indicate a fiscal year end of Decemb
• Neurocrine Biosciences Executive Compensation Filing — DEF 14A · 2025-04-09T00:00:00.000Z [neutral] Risk: low
  Neurocrine Biosciences Inc. filed a DEF 14A on April 9, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. Key individuals lik
• Neurocrine Biosciences Adds New Director — 8-K · 2025-04-04T00:00:00.000Z [neutral] Risk: low
  Neurocrine Biosciences, Inc. announced on April 2, 2025, the election of Dr. David L. M. M.D. to its Board of Directors. Dr. M.D. will serve as a Class II direc
• Neurocrine Biosciences Files 2024 Annual Report — 10-K · 2025-02-10T00:00:00.000Z [neutral] Risk: low
  Neurocrine Biosciences, Inc. filed its annual report for the fiscal year ended December 31, 2024. The company is incorporated in Delaware and headquartered in S
• Neurocrine Biosciences Files 8-K on Financials — 8-K · 2025-02-06T00:00:00.000Z [neutral] Risk: low
  Neurocrine Biosciences, Inc. filed an 8-K on February 6, 2025, reporting on its results of operations and financial condition. The filing includes financial sta
• Neurocrine Biosciences Enters Material Definitive Agreement — 8-K · 2025-01-27T00:00:00.000Z [neutral] Risk: medium
  Neurocrine Biosciences, Inc. (NBIX) announced on January 24, 2025, the entry into a material definitive agreement. The filing also includes information regardin
• Neurocrine Biosciences Files 8-K — 8-K · 2024-12-20T00:00:00.000Z [neutral] Risk: low
  Neurocrine Biosciences, Inc. filed an 8-K on December 20, 2024, to report other events. The filing does not contain specific details about the nature of these e
• Neurocrine Biosciences Files 8-K — 8-K · 2024-11-01T00:00:00.000Z [neutral] Risk: low
  Neurocrine Biosciences, Inc. filed an 8-K on November 1, 2024, reporting an event on October 31, 2024. The filing is categorized under 'Other Events' and does n
• Neurocrine Biosciences Files Q3 2024 10-Q Report — 10-Q · 2024-10-30T00:00:00.000Z [neutral] Risk: low
  Neurocrine Biosciences, Inc. (NBIX) filed its quarterly report for the period ended September 30, 2024. The company is incorporated in Delaware and headquartere
• SC 13G Filing — SC 13G · 2024-10-17T00:00:00.000Z [neutral]
• Neurocrine Biosciences Announces Executive and Director Changes — 8-K · 2024-10-11T00:00:00.000Z [neutral] Risk: medium
  Neurocrine Biosciences, Inc. announced on October 11, 2024, changes in its executive and director roles. Specifically, the company reported the departure of cer
• Neurocrine Biosciences Files 8-K — 8-K · 2024-08-28T00:00:00.000Z [neutral] Risk: medium
  Neurocrine Biosciences, Inc. filed an 8-K on August 28, 2024, to report an Other Event and Regulation FD Disclosure. The filing does not contain specific financ
• Neurocrine Biosciences Q2 2024 Update — 10-Q · 2024-08-01T00:00:00.000Z [neutral] Risk: medium
  Neurocrine Biosciences Inc. reported its financial results for the period ending June 30, 2024. The company's filing indicates ongoing operations in the biologi
• Neurocrine Biosciences Elects New Directors, Amends Bylaws — 8-K · 2024-05-28T00:00:00.000Z [neutral] Risk: low
  Neurocrine Biosciences, Inc. announced on May 24, 2024, a change in its board of directors, with the election of two new directors, Dr. Richard A. F. Clark and
• Neurocrine Biosciences Adds Dr. P. Brandon Davis to Board — 8-K · 2024-05-23T00:00:00.000Z [neutral] Risk: low
  Neurocrine Biosciences, Inc. announced on May 22, 2024, the election of Dr. P. Brandon Davis to its Board of Directors, effective immediately. Dr. Davis, a seas
• Neurocrine Biosciences Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-01T00:00:00.000Z [bullish] Risk: low
  NEUROCRINE BIOSCIENCES INC (NBIX) filed a Quarterly Report (10-Q) with the SEC on May 1, 2024. Revenue for the three months ended March 31, 2024, was $453 milli
• Neurocrine Biosciences Inc. Files Definitive Proxy Statement — DEF 14A · 2024-04-10T00:00:00.000Z [neutral] Risk: low
  NEUROCRINE BIOSCIENCES INC (NBIX) filed a Proxy Statement (DEF 14A) with the SEC on April 10, 2024. Neurocrine Biosciences Inc. filed a Definitive Proxy Stateme
• Vanguard Trims Neurocrine Bio Stake to 10.7% — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral] Risk: low
  The Vanguard Group, a major investment firm, filed an updated SC 13G/A on February 13, 2024, indicating its ownership of 10,766,882 shares of Neurocrine Bioscie
• Neurocrine Biosciences, Inc. Files 2023 Annual Report on Form 10-K — 10-K · 2024-02-09T00:00:00.000Z [neutral] Risk: medium
  NEUROCRINE BIOSCIENCES INC (NBIX) filed a Annual Report (10-K) with the SEC on February 9, 2024. Neurocrine Biosciences, Inc. filed its annual report for the fi
• Neurocrine Biosciences Files 8-K on Financial Results — 8-K · 2024-02-07T00:00:00.000Z [neutral]
  Neurocrine Biosciences, Inc. filed an 8-K on February 7, 2024, to report its results of operations and financial condition. This filing, under Items 2.02 and 9.
• BlackRock Amends Neurocrine Biosciences Stake (SC 13G/A) — SC 13G/A · 2024-01-23T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 23, 2024, indicating a change in its ownership of Neurocrine Biosciences Inc. common stock as of December 31